Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
7 Aug 23
15-12G
Securities registration termination
3 Aug 23
DEFA14A
Additional proxy soliciting materials
3 Aug 23
8-K
Departure of Directors or Certain Officers
3 Aug 23
DEFA14A
Additional proxy soliciting materials
28 Jul 23
8-K
Departure of Directors or Certain Officers
28 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Jul 23
RW
Registration withdrawal request
19 Jul 23
8-K
Termination of a Material Definitive Agreement
19 Jul 23
25-NSE
Exchange delisting
10 Jul 23
8-K
Hilco Streambank Seeks Offers to Acquire Patent Portfolio of Biopharmaceutical Company Oncorus
26 Jun 23
DEF 14A
Definitive proxy
23 Jun 23
PRE 14A
Preliminary proxy
12 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Jun 23
8-K
Departure of Directors or Certain Officers
7 Jun 23
8-K
Oncorus Announces Workforce Reduction Plan
1 Jun 23
10-Q
2023 Q1
Quarterly report
22 May 23
8-K
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
22 May 23
8-K
Termination of a Material Definitive Agreement
18 May 23
NT 10-Q
Notice of late quarterly filing
16 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 May 23
8-K
Departure of Directors or Certain Officers
1 May 23
S-8
Registration of securities for employees
24 Mar 23
10-K
2022 FY
Annual report
24 Mar 23
8-K
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
24 Mar 23
8-K
Regulation FD Disclosure
14 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
30 Nov 22
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
2 Nov 22
8-K
Entry into a Material Definitive Agreement
14 Sep 22
8-K
Regulation FD Disclosure
5 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates
4 Aug 22
8-K
Oncorus Appoints Douglas Fambrough to Board of Directors
23 Jun 22
DEF 14A
Definitive proxy
13 May 22
Latest ownership filings
3
Brian J. Shea
16 Jun 23
3
Alexander Nolte
22 May 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
CHI Advisors LLC
13 Feb 23
SC 13G/A
Arkin Moshe
2 Feb 23
SC 13D/A
Flynn James E
19 Jan 23
SC 13D/A
Flynn James E
17 Jan 23
SC 13D/A
Flynn James E
3 Jan 23
4
James E Flynn
30 Dec 22
4
James E Flynn
27 Dec 22
SC 13D/A
Flynn James E
22 Dec 22
4
James E Flynn
21 Dec 22
4
James E Flynn
15 Dec 22
4
Stephen Harbin
2 Nov 22
SC 13G
K2 HealthVentures Equity Trust LLC
1 Nov 22
SC 13G
BlackRock Inc.
8 Jul 22
4
Barbara Yanni
24 Jun 22
4
Eric Rubin
24 Jun 22
4
Spencer Nam
24 Jun 22
4
Mary Kay Fenton
24 Jun 22
4
LUKE EVNIN
24 Jun 22
4
Scott A Canute
24 Jun 22
4
Mitchell H. Finer
24 Jun 22
4
DOUGLAS FAMBROUGH
24 Jun 22
3
DOUGLAS FAMBROUGH
24 Jun 22
4
Rick Wanstall
25 May 22
4
Rick Wanstall
24 May 22
4
Rick Wanstall
19 May 22
4
Rick Wanstall
16 May 22
4
Rick Wanstall
12 May 22
3
Rick Wanstall
12 May 22
4
John Mayer Goldberg
2 Mar 22
4
Christophe Queva
2 Mar 22
4
John P. McCabe
2 Mar 22
4
Stephen Harbin
2 Mar 22
4
Theodore Ashburn
2 Mar 22
SC 13G/A
PERCEPTIVE ADVISORS LLC
15 Feb 22
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 22
SC 13G/A
CHI Advisors LLC
11 Feb 22
SC 13G
BlackRock Inc.
4 Feb 22